España F, Estellés A, Aznar J, Gilabert J
Thromb Res. 1986 Dec 15;44(6):771-82. doi: 10.1016/0049-3848(86)90023-x.
We studied functional protein C activity, both anticoagulant and amidolytic, as well as protein C antigen in 30 normal subjects, several members of a family with congenital protein C deficiency, 18 patients with severe preeclampsia, 27 patients with coronary heart disease, including 15 patients with myocardial infarction and 12 with angina pectoris, 20 patients on stable oral anticoagulant therapy (thrombotest values: 3-12%) and three patients with disseminated intravascular coagulation. Protein C values measured by the coagulant assay were compared to those obtained with amidolytic and immunochemical assays. In all the groups studied, the activity assays (amidolytic and coagulant) correlated significantly with each other as well as with the immunochemical assay. In patients on oral anticoagulant therapy the coagulant assay gave lower protein C values than amidolytic and immunochemical assays. A good correlation was found between immunological and amidolytic protein C assays (r=0.90, p less than 0.001), immunological and coagulant protein C assays (r=0.93, p less than 0.001), and amidolytic and coagulant protein C assays (r=0.95, p less than 0.001) in all the samples studied without including the protein C values of patients on oral anticoagulant therapy. These results allow us to recommend the functional protein C coagulant assay in patients on stable oral anticoagulant therapy because only this assay evaluates the "in vivo" protein C function in these patients.
我们研究了30名正常受试者、一个患有先天性蛋白C缺乏症的家族中的几名成员、18名重度子痫前期患者、27名冠心病患者(包括15名心肌梗死患者和12名心绞痛患者)、20名接受稳定口服抗凝治疗的患者(凝血酶原时间比值:3 - 12%)以及3名弥散性血管内凝血患者的功能性蛋白C活性(抗凝和酰胺水解活性)和蛋白C抗原。将通过凝血测定法测得的蛋白C值与通过酰胺水解测定法和免疫化学测定法获得的值进行比较。在所有研究组中,活性测定法(酰胺水解和凝血)之间以及与免疫化学测定法均显著相关。在接受口服抗凝治疗的患者中,凝血测定法得出的蛋白C值低于酰胺水解测定法和免疫化学测定法。在所有未纳入接受口服抗凝治疗患者的蛋白C值的研究样本中,免疫化学和酰胺水解蛋白C测定法之间(r = 0.90,p < 0.001)、免疫化学和凝血蛋白C测定法之间(r = 0.93,p < 0.001)以及酰胺水解和凝血蛋白C测定法之间(r = 0.95,p < 0.001)均发现有良好的相关性。这些结果使我们建议对接受稳定口服抗凝治疗的患者采用功能性蛋白C凝血测定法,因为只有该测定法能评估这些患者的“体内”蛋白C功能。